Key takeaways
- ~35–50% Fabry patients with an amenable GLA mutation — the migalastat PA gate (HEK293 assay) · Galafold PI
- Part B Medicare routing for IV enzyme replacement (Fabrazyme, Elfabrio) — vs Part D for oral migalastat · CMS
- HST4 NICE recommended migalastat for amenable mutations (HST4); G-BA deemed the added benefit non-quantifiable · NICE / G-BA
Fabry access turns on a genetic test: only patients with an amenable GLA mutation can take oral migalastat, while the IV enzyme replacement therapies sit in the Part B medical benefit with no US biosimilar to discipline cost, and their single-orphan Fabry indication keeps them out of IRA Medicare price negotiation.
The US Fabry payer landscape is defined first by a diagnostic gate. Migalastat (Galafold) is reimbursed only for patients whose GLA mutation is amenable to pharmacological chaperoning (roughly 35–50% of patients), confirmed by a validated cell-based (HEK293) assay. Payers universally require the assay result before authorising migalastat, and its 4–6 week turnaround creates an access lag relative to enzyme replacement, which can be started once the Fabry diagnosis is confirmed. This makes a genetic test, not just clinical severity, the pivotal determinant of oral versus intravenous therapy.
The second axis is benefit routing and price. The intravenous enzyme replacement therapies, agalsidase beta (Fabrazyme) and pegunigalsidase alfa (Elfabrio), route to the Medicare Part B medical benefit (no out-of-pocket cost for dual-eligible patients), while oral migalastat routes to Part D, creating an out-of-pocket differential for non-LIS Medicare patients. Fabrazyme is among the longest-running ultra-high-cost Part B biologics in rare disease and has no US biosimilar; European agalsidase alfa (Replagal) is not FDA-approved. Because its only approved indication is Fabry disease, however, Fabrazyme falls under the IRA's orphan-drug exclusion and is not eligible for Medicare price negotiation. On the HTA side, NICE recommended migalastat for patients with amenable mutations (Highly Specialised Technology guidance HST4, 2017), while Germany's G-BA, treating it as an orphan drug, deemed its additional benefit proven by approval but non-quantifiable in extent — European precedents that US payers reference informally.
US Fabry agent payer status — 2026
| Drug (Brand / INN) | Benefit Routing | HTA / ICER Status | PA Criteria (Commercial) | Key Payer Risk |
|---|---|---|---|---|
| Fabrazyme (agalsidase beta) | Medicare Part B (IV administered) | No US ICER review; agalsidase ERT not separately NICE-appraised | Confirmed Fabry (GLA enzyme + pathogenic variant) with end-organ involvement | No US biosimilar to discipline WAC; IRA orphan-drug exclusion shields it from Medicare negotiation |
| Galafold (migalastat) | Medicare Part D (oral) | NICE HST4: recommended for amenable mutations; G-BA: non-quantifiable orphan benefit | Amenable GLA mutation via validated HEK293 assay + confirmed Fabry diagnosis | Amenability-assay gate (4–6 wk lag); Part D OOP vs Part B ERT |
| Elfabrio (pegunigalsidase alfa) | Medicare Part B (IV administered) | No ICER review; FDA/EMA approved on BALANCE non-inferiority | Confirmed Fabry + symptomatic; switch from Fabrazyme requires clinical rationale | Non-inferiority framing insufficient for switch at some plans |
Sources: NICE Highly Specialised Technology guidance HST4 (2017) — migalastat for Fabry; G-BA / IQWiG 2016 migalastat early benefit assessment (AMNOG, non-quantifiable orphan added benefit); CMS IRA Drug Price Negotiation framework (orphan-drug exclusion) and Part B Drug Spending Dashboard; FDA Drugs@FDA; major payer coverage policies.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How does the amenable-mutation assay function as a prior-authorisation gate for oral migalastat, and what access lag does it create? • • Amenable-mutation assay (HEK293) as the universal PA requirement • The ~35–50% amenable fraction and its effect on the addressable pool • 4–6 week assay turnaround and the access lag vs ERT • Oral vs IV eligibility determination in practice
- How does Part B vs Part D benefit routing shape patient out-of-pocket cost and payer incentives across ERT and the oral chaperone? • • Part B (no OOP for dual-eligible) for IV ERT vs Part D coinsurance for migalastat • Commercial tier and OOP differentials • Payer economic incentives around oral vs IV • Switching considerations between the two ERTs
- How does the IRA orphan-drug exclusion protect Fabrazyme's pricing, and how do NICE and G-BA HTA outcomes inform US payer posture? • • IRA orphan-drug exclusion: why sole-Fabry-indication ERT is exempt from negotiation • Absence of a US agalsidase biosimilar and its pricing effect • NICE HST4 positive recommendation for amenable mutations • G-BA / AMNOG non-quantifiable orphan-benefit assessment and US read-across
What's inside
-
1 · US Payer Landscape Overview — Fabry Coverage Architecture 4 pp
- Why the Fabry payer landscape is defined first by a diagnostic gate rather than clinical severity alone.
- How benefit routing splits between Part B enzyme replacement and Part D oral migalastat shapes access.
-
2 · The Amenable-Mutation Assay as a PA Gate 5 pp
- Why only about 35-50% of Fabry patients have a GLA mutation amenable to migalastat, per the validated HEK293 assay.
- How the assay's 4-6 week turnaround creates an access lag relative to enzyme replacement therapy.
-
3 · Part B vs Part D Routing — OOP & Access Implications 4 pp
- Why Fabrazyme and Elfabrio route to Medicare Part B with no out-of-pocket cost for dual-eligible patients.
- How oral migalastat's Part D routing creates an out-of-pocket differential for non-LIS Medicare patients.
-
4 · ERT Pricing, IRA Orphan Exclusion & the Biosimilar Gap 5 pp
- Why Fabrazyme's sole Fabry indication qualifies it for the IRA's orphan-drug exclusion from Medicare price negotiation.
- How the absence of a US agalsidase biosimilar leaves no competitive check on Fabrazyme's ultra-high-cost WAC.
-
5 · HTA Precedent — NICE HST4 & G-BA / AMNOG 4 pp
- Why NICE's 2017 HST4 guidance recommended migalastat only for patients with amenable mutations.
- How Germany's G-BA deemed migalastat's added orphan-drug benefit proven yet non-quantifiable in extent.
-
6 · Commercial Payer PA Criteria & Switching Policy 3 pp
- Why commercial plans require confirmed Fabry diagnosis with end-organ involvement before authorizing enzyme replacement.
- How Elfabrio's BALANCE non-inferiority data is often insufficient alone to justify a switch from Fabrazyme.
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Fabry Payer & HTA is built for market access, HEOR, and pricing teams navigating the migalastat amenability gate, Part B/D routing, and ERT pricing exposure in the US Fabry market. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (IRA, HTA, PA criteria), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, HTA precedent, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Fabry P&HTA is built from HTA body publications, CMS pricing and benefit documentation, FDA regulatory records, and live payer formulary and PA policy documents from major US commercial plans.
Key sources: NICE Highly Specialised Technology guidance HST4 (2017) for migalastat; G-BA / IQWiG 2016 migalastat early benefit assessment (AMNOG); CMS IRA Drug Price Negotiation framework and Part B Drug Spending Dashboard; FDA Drugs@FDA; and current commercial payer coverage policies.
- NICE migalastat recommendation verified against NICE Highly Specialised Technology guidance HST4 (2017)
- G-BA non-quantifiable orphan added-benefit determination verified against the 2016 AMNOG early benefit assessment
- Part B vs Part D routing verified against CMS drug classification and benefit design
- Fabrazyme confirmed exempt from IRA negotiation under the sole-orphan-indication exclusion (CMS IRA negotiation framework)
Frequently asked questions
Access Why does migalastat require genetic testing before coverage?
Migalastat only works for patients whose GLA mutation is 'amenable' to pharmacological chaperoning — about 35–50% of Fabry patients. US payers require confirmation of an amenable mutation via a validated cell-based (HEK293) assay before authorising the drug. The assay's 4–6 week turnaround adds an access lag compared with enzyme replacement therapy, which can begin once the Fabry diagnosis is confirmed.
HTA How do NICE and G-BA view Fabry therapies?
NICE recommended migalastat for patients with amenable mutations in its Highly Specialised Technology guidance HST4 (2017). Germany's G-BA, treating migalastat as an orphan drug under the AMNOG process, deemed its additional benefit proven by approval but non-quantifiable in extent. US payers do not follow either body formally but reference these outcomes in prior-authorisation reasoning.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.